We aim to clarify the incidence of AIMSS in AI monotherapy treatment in postmenopausal women with metastatic disease and the impact of the recent addition of CDK4/6 inhibitors on this common adverse event. This evidence concerns the gene CDK4 and metastatic neoplasm.